Abiopharma

Amaero Ltd engages in the research, development, manufacture, and sale of refractory metals and specialty alloy powders in the United States. It serves defense, space, and aviation industries. The principal activity of Amaero is the provision of end to end additive manufacturing solutions in terms of services, equipment and technology to its key clients in the Aviation Defense and Space sectors and the Tool and Die industry. Amaero was established with the support of Monash University in 2013 to commercialize opportunities in metal 3D printing identified by the Monash Centre for Additive Manufacturing (MCAM). Amaero has worked with many of the worlds leading manufacturers of aerospace and defense products in both an R&D and manufacturing capacity and has a demonstrated ability to deliver aviation and military specification 3D printed alloy critical operation components.

Additional info from OTC:
Amaero Ltd engages in the research, development, manufacture, and sale of refractory metals and specialty alloy powders in the United States. It serves defense, space, and aviation industries. The principal activity of Amaero is the provision of end to end additive manufacturing solutions in terms of services, equipment and technology to its key clients in the Aviation Defense and Space sectors and the Tool and Die industry. Amaero was established with the support of Monash University in 2013 to commercialize opportunities in metal 3D printing identified by the Monash Centre for Additive Manufacturing (MCAM). Amaero has worked with many of the worlds leading manufacturers of aerospace and defense products in both an R&D and manufacturing capacity and has a demonstrated ability to deliver aviation and military specification 3D printed alloy critical operation components.